EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Longitudinal Changes in Insulin Resistance Indices During SGLT2 Inhibitor Therapy in Type 2 Diabetes: A Prospective Observational Cohort Study

Ahmet Altintas, Mehmet Turan Ozer, Omer Tepe, Abdullah Sariyildirim

International Journal of Translational Medicine · 2026-11-06 · 6 (4) · 52

DOI: 10.3390/ijtm6040052 ↗
AbstractBibliografische Angaben

Abstract

Background/Objectives: Glucose-lowering treatment can change insulin resistance indices without demonstrating improved insulin sensitivity. We described these changes during sodium–glucose cotransporter-2 (SGLT2) inhibitor therapy in routine care. Methods: In this prospective, uncontrolled observational cohort, 54 adults with type 2 diabetes were assessed at baseline, 3 and 6 months. Background medication was abstracted from hospital and prescription records. Exploratory baseline-to-6-month comparisons used Wilcoxon signed-rank tests with Benjamini–Hochberg adjustment across 15 analysed outcomes. Results: Median HOMA-IR decreased from 8.38 (IQR 3.47–13.26) to 3.14 (2.19–4.39), a 62.6% reduction in group medians (rank-biserial r = −0.79; adjusted p < 0.001); in the 41 participants without documented insulin use, the reduction was 50.9% (r = −0.76). Median triglyceride–glucose (TyG) index decreased from 9.45 to 9.04 (−4.3%; r = −0.63; adjusted p < 0.001). Change in HOMA-IR was not significantly correlated with change in HbA1c (ρ = −0.15; p = 0.27). Conclusions: Both indices decreased during follow-up, including in participants without documented insulin use, but these observations cannot establish a treatment effect or improved insulin sensitivity. TyG requires no insulin measurement but remains sensitive to glucose- and triglyceride-lowering therapies, including SGLT2 inhibitors. Controlled studies with direct measures of insulin sensitivity are needed.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →